These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 15342366

  • 1. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML.
    Cancer Res; 2004 Sep 01; 64(17):5913-9. PubMed ID: 15342366
    [Abstract] [Full Text] [Related]

  • 2. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F, Goncalves A, Monges G, Madroszyk A, Guiramand J, Moutardier V, Noguchi T, Dubreuil P, Sobol H.
    Oncol Rep; 2006 Jul 01; 16(1):97-101. PubMed ID: 16786129
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S, Schütte J.
    Cancer Chemother Pharmacol; 2003 Mar 01; 51(3):261-5. PubMed ID: 12655446
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.
    Clin Cancer Res; 2007 Jan 01; 13(1):170-81. PubMed ID: 17200352
    [Abstract] [Full Text] [Related]

  • 7. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T, Pavan GM, Virdis E, Greco A, Fermeglia M, Sandri M, Pricl S, Pierotti MA, Pilotti S, Tamborini E.
    J Natl Cancer Inst; 2009 Feb 04; 101(3):194-204. PubMed ID: 19176456
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S, Pan YL, Tao DY, Wang JL, Huang KE.
    Scand J Gastroenterol; 2009 Feb 04; 44(6):760-3. PubMed ID: 19096980
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Feb 04; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 14. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K, Matsumoto T, Hirota S.
    Gan To Kagaku Ryoho; 2009 Jul 04; 36(7):1080-5. PubMed ID: 19620796
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J, Miettinen M.
    Histopathology; 2008 Sep 04; 53(3):245-66. PubMed ID: 18312355
    [Abstract] [Full Text] [Related]

  • 16. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L.
    Ann Surg Oncol; 2007 Feb 04; 14(2):526-32. PubMed ID: 17139461
    [Abstract] [Full Text] [Related]

  • 17. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P.
    Clin Cancer Res; 2006 Mar 15; 12(6):1743-9. PubMed ID: 16551858
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 15; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.